Skip to main content

QNCX

Stock
Health Care
Biotechnology

Performance overview

QNCX Price
Price Chart

Forward-looking statistics

Beta
1.19
Risk
88.43%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.

Company info

SectorHealth Care
IndustryBiotechnology
Employees22
Market cap$34.1M

Fundamentals

Enterprise value$59.2M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity84.77

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.39
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$500K
Avg trading volume (10 day)$479K
Put-call ratio—

Macro factor sensitivity

Growth-7.0
Credit+8.2
Liquidity+4.4
Inflation-5.3
Commodities-1.6
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-5.19
Price to sales—
P/E Ratio-5.19
Enterprise Value to Revenue—
Price to book3.82

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma

Two microcap biotech stocks to consider for the science-challenged among us.

Zacks Investment Research (March 7, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free